Patient Summary

Drug List - Brand Name to Generic Identification

Clinical Rationale for Each Drug

1. Inj. Pantoprazole (Paridem) 40mg BD

• Rationale: Gastroprotection, especially important since the patient is on dual antiplatelet therapy (Aspirin + Clopidogrel), which significantly raises GI bleed risk. PPI co-prescription with DAPT is a standard of care. Also covers the Mucaine gel use for possible gastric symptoms/reflux.
• Route: IV because patient may have reduced oral intake in acute setting.

2. Inj. Ondansetron (Neomit) 4mg BD

• Rationale: The patient has loose motions (diarrhea) and giddiness - likely experiencing nausea/vomiting as part of her presentation. Ondansetron is a 5-HT3 receptor antagonist used for acute nausea and vomiting.
• Concern: Ondansetron can prolong the QT interval. Given the patient's cardiac history (post-PTCA) and concurrent medications, QTc monitoring is advisable.

3. Inj. Optineuron OD (B-Complex: B1+B2+B6+B12+Nicotinamide+D-Panthenol)

• Rationale: Neurotrophic support for TIA recovery and peripheral neuropathy. In diabetic patients, B12 deficiency (worsened by metformin if used) and peripheral neuropathy are common. B1 (thiamine) is also important in vascular neurological conditions.

4. Tab. Alprazolam (Restyl) 0.25mg OD

• Rationale: Anxiety/agitation management in the acute setting. The patient likely has significant psychological distress following a TIA diagnosis.
• Concern (IMPORTANT): Benzodiazepines are generally discouraged in elderly patients with TIA/stroke due to risk of falls, sedation, and cognitive impairment. In a 63-year-old with dizziness, this requires careful monitoring. Short-term use only; lowest possible dose is appropriate.

5. Liq. Mucaine Gel TID

• Rationale: Combination antacid + local mucosal anesthetic for gastric/esophageal symptoms, likely gastritis or reflux symptoms secondary to stress or medications (Aspirin irritates the gastric mucosa).

6. Tab. Stamlo 5mg OD (Amlodipine - regular)

• Rationale: Antihypertensive - calcium channel blocker. With BP 190/100 on admission and known HTN, amlodipine is a first-line agent. It is also appropriate in post-PTCA patients and those with DM.

7. Tab. Ecosprin 75mg OD (Aspirin)

• Rationale: Core antiplatelet therapy for TIA secondary prevention. Per guidelines (Rosen's Emergency Medicine, Goldman-Cecil), dual antiplatelet therapy (Aspirin + Clopidogrel) initiated within 24 hours of TIA/minor stroke and continued for up to 21 days significantly reduces recurrent stroke risk (POINT and CHANCE trials). In this post-PTCA patient, aspirin is also essential for stent patency.

8. Inj. Mucomix BD (N-Acetylcysteine)

• Rationale: This is likely being used as an antioxidant and free-radical scavenger for neuroprotection in the context of TIA, or as a mucolytic. NAC has antioxidant properties and supports glutathione synthesis. Some centers use it off-label in cerebrovascular events. It may also address any respiratory secretions if the patient has any pulmonary issue.

9. Tab. Clopitab 75mg OD (Clopidogrel)

• Rationale: Second antiplatelet agent forming DAPT with Aspirin. Per CHANCE and POINT trials, Clopidogrel + Aspirin dual therapy for 21 days after TIA reduces recurrent ischemic events by ~25% compared to aspirin alone. In this patient who is also post-PTCA, clopidogrel is doubly indicated.
• Note: The classic practice is to give a loading dose (300-600mg) on day 1. The prescription shows 75mg OD - if this is after the loading dose was given, it is appropriate maintenance.

10. Tab. Nuhenz OD (Mecobalamin + B6 + Folic acid + Benfotiamine + Myo-Inositol + Chromium)

• Rationale: Targeted at diabetic neuropathy management - this patient has DM, and symptoms like left arm pain, weakness, and numbness can have a neuropathic component. Benfotiamine (fat-soluble B1) is specifically beneficial in diabetic neuropathy. Myo-Inositol helps with nerve conduction in diabetics.

11. Tab. Vertin 16mg SOS (Betahistine)

• Rationale: For vertigo/dizziness episodes. The patient presents with giddiness and dizziness. Betahistine acts on H1 and H3 histamine receptors to improve microcirculation in the inner ear and vestibular system. Given SOS (as needed) rather than regular, suggesting it is symptomatic relief only.

12. Tab. Amlopin 5mg SOS (Amlodipine - SOS)

• Concern - POTENTIAL DUPLICATION: The patient is already on Tab. Stamlo 5mg OD (which is also Amlodipine 5mg). Amlopin SOS is the same drug as Stamlo OD. Giving an SOS dose of the same calcium channel blocker when the patient is already on a regular dose is a prescribing concern - this could lead to excessive hypotension, especially with dizziness already present. This should be clarified - it may be intended for hypertensive urgency (BP spike management), but the risk of compounding CCB doses needs to be recognized.

13. Inj. Human Actrapid 40IU SOS (Regular Insulin)

• Rationale: Sliding scale / SOS insulin for acute hyperglycemia management in this known diabetic patient. In acute cerebrovascular events, maintaining euglycemia (avoiding both hyperglycemia and hypoglycemia) is important as hyperglycemia worsens neurological outcomes. 40IU SOS is the maximum dose to be given if blood glucose crosses a threshold - the nursing staff should confirm the glucose threshold triggering this dose.
• Concern: 40IU of regular insulin SOS is a very high dose for a single administration. This requires careful monitoring; the dose may need to be confirmed/clarified with the prescriber. Typically, sliding scales use 4-10 IU increments.

14. Inj. Stemetil SOS (Prochlorperazine)

• Rationale: Phenothiazine antiemetic and anti-vertigo agent, given SOS for breakthrough nausea, vomiting, or severe vertigo episodes. Used alongside Ondansetron (Neomit) scheduled doses for comprehensive emesis control.

Summary of Key Clinical Points

Dual Antiplatelet Therapy (DAPT) - Appropriate

Hypertension Management

Diabetic Management

Red Flags / Prescribing Concerns

Missing Drug to Flag